JUŘICA, Jan, Roman GONĚC, Adéla BÁRTOVÁ and Jana GREGOROVÁ. Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience. European Pharmaceutical Journal. Warsaw: Sciendo, 2022, vol. 69, s1, p. 84-86. ISSN 2453-6725. Available from: https://dx.doi.org/10.2478/afpuc-2022-0006.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience
Name in Czech Imunitně podímněné nežádoucí účinky Checkpoint iinhibitorů: klinická zkušenost
Name (in English) Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience
Authors JUŘICA, Jan (203 Czech Republic, guarantor, belonging to the institution), Roman GONĚC (203 Czech Republic), Adéla BÁRTOVÁ (203 Czech Republic, belonging to the institution) and Jana GREGOROVÁ (203 Czech Republic, belonging to the institution).
Edition European Pharmaceutical Journal, Warsaw, Sciendo, 2022, 2453-6725.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW URL
RIV identification code RIV/00216224:14110/22:00128009
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.2478/afpuc-2022-0006
Keywords (in Czech) Inhibitory imunitního kontrolního bodu; imunoterapie; nežádoucí účinek; autoimunita
Keywords in English Immune checkpoint inhibitors; immunotherapy; adverse effect; autoimmunity
Tags rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 21/2/2023 14:45.
Abstract
Autoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 patients. Severe irAEs were pronounced in 83 patients (12.8%). Further, we report a case of severe irAE after treatment with ipilimumab and nivolumab. Prednisone, mesalazine, octreotide, infliximab, vedolizumab, and mycophenolate mofetil were used to manage G4 colitis, with partial response. Early diagnosis and appropriate management of irAE are essential in the perspective of further oncological treatment.
Abstract (in English)
Autoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 patients. Severe irAEs were pronounced in 83 patients (12.8%). Further, we report a case of severe irAE after treatment with ipilimumab and nivolumab. Prednisone, mesalazine, octreotide, infliximab, vedolizumab, and mycophenolate mofetil were used to manage G4 colitis, with partial response. Early diagnosis and appropriate management of irAE are essential in the perspective of further oncological treatment.
Links
MUNI/A/1440/2021, interní kód MUName: Preklinický a klinický výzkum Farmakologického ústavu v oblasti farmakokinetiky, neurobiologie závislostí a personalizované farmakoterapie v onkologii (Acronym: Farm-Pre-Klin)
Investor: Masaryk University
ROZV/28/LF10/2020, interní kód MUName: Metabolické profilování nizkomolekulárních látek pomocí hmotnostní spektrometrie
Investor: Ministry of Education, Youth and Sports of the CR, Internal development projects
PrintDisplayed: 24/6/2024 10:44